What is he best known for?
The fields of study he is best known for:
Dharminder Chauhan mainly investigates Cancer research, Bone marrow, Proteasome inhibitor, Multiple myeloma and Bortezomib.
His work deals with themes such as Cell culture, Cell growth, Apoptosis, Immunology and Histone deacetylase, which intersect with Cancer research.
His Cell culture research incorporates elements of Cell and Cytotoxicity.
His research in Bone marrow intersects with topics in Natural killer cell and Stromal cell.
Dharminder Chauhan combines subjects such as Retinoblastoma, Leukemia and Pharmacology with his study of Multiple myeloma.
His study in Bortezomib is interdisciplinary in nature, drawing from both Ubiquitin, Cancer cell, IκBα, Proteasome and IκB kinase.
His most cited work include:
- The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. (1394 citations)
- NF-κB as a Therapeutic Target in Multiple Myeloma * (856 citations)
- Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. (853 citations)
What are the main themes of his work throughout his whole career to date?
Dharminder Chauhan spends much of his time researching Cancer research, Bortezomib, Multiple myeloma, Bone marrow and Cell culture.
His Cancer research study incorporates themes from Immunology, Apoptosis, Cell growth and Cytotoxicity.
In his research, Gene expression is intimately related to Molecular biology, which falls under the overarching field of Apoptosis.
His Bortezomib study combines topics from a wide range of disciplines, such as Proteasome inhibitor, Proteasome, Cancer cell, Pharmacology and In vivo.
The concepts of his Multiple myeloma study are interwoven with issues in Immune system and Dexamethasone.
His Bone marrow study integrates concerns from other disciplines, such as Peripheral blood mononuclear cell, Angiogenesis and CD40.
He most often published in these fields:
- Cancer research (64.29%)
- Bortezomib (42.40%)
- Multiple myeloma (33.64%)
What were the highlights of his more recent work (between 2013-2021)?
- Cancer research (64.29%)
- Multiple myeloma (33.64%)
- Bortezomib (42.40%)
In recent papers he was focusing on the following fields of study:
His main research concerns Cancer research, Multiple myeloma, Bortezomib, Ubiquitin and Cancer cell.
His research integrates issues of Cell culture, Cell growth and Immune system, Immunology, Bone marrow in his study of Cancer research.
He has included themes like CD40, Tumor microenvironment, Immunogenic cell death, Stem cell and Cytotoxicity in his Multiple myeloma study.
His Bortezomib research is multidisciplinary, relying on both Proteasome inhibitor and Proteasome.
The various areas that Dharminder Chauhan examines in his Ubiquitin study include Receptor and Cell biology.
His Pomalidomide research focuses on Pharmacology and how it relates to Apoptosis.
Between 2013 and 2021, his most popular works were:
- The proteasome and proteasome inhibitors in multiple myeloma (113 citations)
- Structure-Guided Development of a Potent and Selective Non-covalent Active-Site Inhibitor of USP7 (78 citations)
- Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells. (52 citations)
In his most recent research, the most cited papers focused on:
His primary areas of investigation include Cancer research, Multiple myeloma, Bortezomib, Proteasome and Pomalidomide.
His work carried out in the field of Cancer research brings together such families of science as DNA damage, Apoptosis, Histone deacetylase, DNA repair and Kinase.
His Multiple myeloma research includes elements of Immune system, Immunity, Bone marrow and Cytotoxicity.
His studies in Bortezomib integrate themes in fields like Proteasome inhibitor, Cell growth and Pharmacology.
His work focuses on many connections between Cell growth and other disciplines, such as Immunology, that overlap with his field of interest in Nicotinamide phosphoribosyltransferase.
His biological study spans a wide range of topics, including Enzyme activator and Caspase.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
